This handout photo released by the University of Maryland School of Medicine on Monday shows surgeons performing a transplant of a heart from a genetically modified pig to patient David Bennett, in Baltimore, Maryland, last Friday.
Surgeons in the United States have successfully implanted a heart from a genetically modified pig in a 57-year-old man, a medical first that could one day help solve the chronic shortage of organ donations.
The “historic” procedure took place last Friday, the University of Maryland Medical School said in a statement on Monday. While the patient’s prognosis is far from certain, it represents a major milestone for animal to human transplantation.
The patient, David Bennett, had been deemed ineligible for human transplant – a decision that is often taken when the recipient has very poor underlying health.
He is now recovering and being carefully monitored to determine how the new organ performs.
“It was either die or do this transplant. I want to live. I know it’s a shot in the dark, but it’s my last choice,” the Maryland resident said a day before the surgery.
Bennett, who has spent the last several months bedridden on a heart-lung bypass machine, added: “I look forward to getting out of bed after I recover.”
The Food and Drug Administration granted emergency authorization for the surgery on New Year’s Eve, as a last-ditch effort for a patient who was unsuitable for conventional transplant. “This was a breakthrough surgery and brings us one step closer to solving the organ shortage crisis,” said Bartley Griffith, who surgically transplanted the pig heart.
“We are proceeding cautiously, but we are also optimistic that this first-in-the-world surgery will provide an important new option for patients in the future.”
Surgeon Dr. Bartley Griffith (L) with patient David Bennett, who received a heart implant from a genetically modified pig, in Baltimore, Maryland.
Muhammad Mohiuddin, who co-founded the university’s cardiac xenotransplantation program, added the surgery was the culmination of years of research, involving pig-to-baboon transplants, with survival times that exceeded nine months.
“The successful procedure provided valuable information to help the medical community improve this potentially life-saving method in future patients,” he said.
Bennett’s donor pig belonged to a herd that had undergone genetic editing procedures.
Three genes that would have led to rejection of pig organs by humans were “knocked out,” as was a gene that would have led to excessive growth of pig heart tissue. Six human genes responsible for human acceptance were inserted into the genome, for a total of 10 unique gene edits.
The editing was performed by Virginia-based biotech firm Revivicor, which also supplied the pig used in a breakthrough kidney transplant on a brain dead patient in New York in October.
But while that surgery was purely a proof-of-concept experiment, and the kidney was connected outside the patient’s body, the new surgery is intended to save a person’s life.
The donated organ was kept in an organ-preservation machine ahead of the surgery, and the team also used an experimental new drug made by Kiniksa Pharmaceuticals along with conventional anti-rejection drugs to suppress the immune system.
About 110,000 Americans are currently waiting for an organ transplant, and more than 6,000 patients die each year before getting one, according to official figures.
To meet demand, doctors have long been interested in so-called xenotransplantation, or cross-species organ donation, with experiments tracing back to the 17th century.